SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22% SLD 0.42 ▲0.00% MBG 0.21 ▲0.00% FDC 3.93 ▼-0.76% LF1 1.87 ▼-2.12% LGF 2.38 ▲0.86% DN1 98.00 ▼-0.17% WMX 1.58 ▼-2.46% RG8 2.52 ▲0.40% CTS 0.89 ▲2.89% TET 0.42 ▲1.20% MRE 1.68 ▲0.00% BST 0.27 ▲3.85% EFR 0.01 ▲0.00% RIV 1.20 ▼-0.42% KIT 1.80 ▲0.56% EMUCA 0.89 RF1 3.38 ▲0.00% AIX 9.00 ▲0.22%

IDT IDT Australia Limited

Healthcare · Drug Manufacturers - Specialty & Generic · website
$0.04
52wk 0.03 – 0.07
Overall
51.9
Value
81.7
Growth
72.8
Health
58.3
Quality
0.0
Momentum
27.6
Dividend
—
Price
About IDT Australia Limited

IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (API) and finished dose forms (FDF) products in Australia, Asia, Europe, and the United States. The company offers integrated services, including development, analytical testing, clinical packaging; and microbiological and analytical testing, clinical packaging, and pharmacy services. It also provides formulation and manufacture of speciality orals (medicinal cannabis) and advanced therapies; psychedelics and medicinal cannabis; oral finished doses; and aseptic fill and finish solutions for liquid and lyophilised forms. In addition, the company offers mRNA and antibody drug conjugates. Further, the company provides contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.

Price analytics

Returns

1 day -6.8%
1 week -8.9%
1 month -10.9%
3 months 28.1%
6 months -8.9%
1 year -30.5%
3 years -32.8%

Risk

Volatility (1y ann.) 72.7%
Beta vs ASX 200 0.56
Sharpe (1y) -0.21
VaR 95% (1-day) -6.2%
Max drawdown (1y) -52.3%
Off 1-year high -36.9%

Technicals

RSI(14) 31
vs 50DMA -7.4%
vs 200DMA -4.2%
Trend Golden cross
Fundamental trends
Financial statements
Loading…
Scoring breakdown (2 Oct 2026)
Value 81.7
Trailing P/E
—
Forward P/E
100
PEG ratio
10
EV / EBITDA
100
Price / Book
98
Price / Sales
99
Growth 72.8
Revenue growth (1y)
46
Revenue CAGR (3y)
100
EPS growth (1y)
—
EPS CAGR (3y)
—
Financial Health 58.3
Net debt / EBITDA
—
Interest coverage (EBIT/interest)
0
Current ratio
90
Debt / Equity
80
Quality (Profitability & Cash Flow) 0.0
Return on equity
0
Return on assets
0
Operating margin
0
Net margin
0
Cash conversion (OCF / net income)
—
Dividend / Income —
No meaningful dividend — pillar excluded from the overall score.
Momentum 27.6
6-month return vs ASX 200
30
Price vs 200-day average
36
Price vs 50-day average
13
Position in 52-week range
28

Hover a row's info icon for the exact rule. Bounds and weights are configurable in the Django admin (Scoring configuration).

Score history
Key metrics
Market cap
$17.57M
P/E (trailing)
—
P/E (forward)
4.10
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.93
EV / EBITDA
-35.79
Price / Book
0.91
ROE
-13.3%
Operating margin
-7.0%
Net margin
-13.3%
Total cash
$2.62M
Total debt
$10.82M
Current ratio
2.33
Debt / Equity
0.57
Free cash flow
$-998,875
Avg volume
169,075
Latest annual results (FY ending 30 Jun 2026)
  • Revenue$20.36M
  • Gross profit$15.91M
  • Operating income-$1.65M
  • Net income-$2.72M
  • Diluted EPS-0.01
  • Free cash flow-$243.00K
  • Net debt$8.31M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $84.15B — 54.3
RMD $45.86B 21.2 74.4
SIG $29.91B 43.3 55.6
FPH $21.64B 57.5 71.1
PME $16.34B 61.8 69.0
RHC $12.56B 40.0 40.2
SHL $9.12B 15.0 43.0
COH $8.20B 55.5 39.4